ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 174

Genetic Association On Disease Severity In Rheumatoid Arthritis: A Validation Study In Japanese Patients

Shinji Yoshida1, Katsunori Ikari1, Koichiro Yano1, Yoshiaki Toyama2, Atsuo Taniguchi3, Hisashi Yamanaka1 and Shigeki Momohara3, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Japanese, joint destruction, polymorphism, rheumatoid arthritis (RA) and severity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The disease severity of rheumatoid arthritis (RA) is objectively measured by radiographic joint destruction, which is reflective of the cumulative burden of inflammation. Recently, the heritability has been proven to be partly involved in progression of joint destruction in RA, and several genetic variants and gene-gene interactions have been reported to be associated with progression of joint destruction in European multi-cohort studies. However, the presence of genetic heterogeneity in RA susceptibility genes has been demonstrated in many population-based studies, and the genetic predisposition factors for progression of joint destruction remain to be poorly understood in Asian patients with RA. The purpose of this study was to identify genetic variants associated with progression of joint destruction in Japanese patients with RA. 

Methods:

This study included 865 Japanese patients with RA for whom Sharp/van der Heijde scores (SHS) of hands were available at a disease duration of 5 years. DNA samples of the subjects were obtained from the Institute of Rheumatology Rheumatoid Arthritis cohort study (IORRA) DNA collection. All of the patients who donated DNA samples consented to participate in this study in accordance with the process approved by the Tokyo Women’s Medical University Genome Ethics Committee, and satisfied the American College of Rheumatology 1987 revised criteria for the classification of RA. Nine of the single nucleotide polymorphisms (SNPs) reported in European multi-cohort studies were selected and genotyped in the DNA samples: rs6821171, and rs1521761 which is in absolute linkage disequilibrium (r2=1) with rs7667746, in interleukin15 (IL15); rs8192916, in granzyme B (GZMB); rs1896368, rs1896367, rs1528873, and rs10762715, in Dickkopf-1 (Dkk-1); rs4792909, and rs6503475, in sclerostin (Sost). SNP genotyping was performed by using the TaqMan fluorogenic 5’ nuclease assay (Applied Biosystems, Tokyo, Japan). Univariate linear regression analyses were performed to examine the association of each SNP and several combinations of SNPs with progression of joint destruction in the first 5 years after onset of RA, calculated as SHS of hands at the 5-year disease duration. All SHS were log-transformed to obtain a normal distribution. 

Results:

Univariate linear regression analyses revealed that all of the SNPs and combinations of SNPs tested in this study were not associated with progression of joint destruction (Table 1). 

Conclusion:

Genetic variants in IL15, GZMB, Dkk-1, and Sostwere not associated with progression of joint destruction in Japanese patients with RA. These results indicate the presence of genetic heterogeneity in risk loci of progression of joint destruction in RA between Caucasian and Asian patients. The heritability of the rate of joint destruction might be different among ethnic populations. 

Table 1

Gene

SNP

Allele (minor/major)

MAF

Tested model

β

P value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

L15

rs6821171

 

C/A

0.30

additive

recessive

-0.05

-0.13

0.48

0.36

 

 

 

 

 

 

 

 

rs1521761

T/A

0.15

additive

recessive

-0.10

-0.13

0.21

0.36

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GZMB

rs8192916

A/G

0.45

additive

recessive

-0.01

0.05

0.91

0.65

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dkk-1

rs1896368

A/G

0.42

additive

recessive

0.07

0.12

0.21

0.16

 

 

 

 

 

 

 

 

rs1896367

A/G

0.30

additive

recessive

-0.11

-0.13

0.09

0.31

 

 

 

 

 

 

 

 

rs1528873

C/A

0.22

additive

recessive

-0.07

-0.02

0.28

0.90

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dkk-1

Sost

rs1528873

rs6503475

C/A

G/A

0.22

0.45

additive

-0.02

0.59

 

 

 

 

 

 

 

 

rs10762715

rs4792909

T/C

T/G

0.22

0.40

additive

0.01

0.78

 

 

 

 

 

 

 

 

rs10762715

rs6503475

T/C

G/A

0.22

0.45

additive

0.02

0.59


Disclosure:

S. Yoshida,
None;

K. Ikari,

Pfizer, Takeda,

2,

Asahikasei, AbbVie, Astellas, Eisai, Kaken, Mitsubishi Tanabe, Taisho Toyama,

8;

K. Yano,
None;

Y. Toyama,
None;

A. Taniguchi,
None;

H. Yamanaka,

Abbott, AbbVie, Asahikasei , Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taishotoyama, Takeda, Teijin,

2,

Abbott, AbbVie, Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, Takeda, Teijin,

5,

Abbott, AbbVie, Astellas, Bristol-Myers Squib, Chugai, Eisai, Mitsubishi Tanabe, Pfizer, Takeda, Teijin,

8;

S. Momohara,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-association-on-disease-severity-in-rheumatoid-arthritis-a-validation-study-in-japanese-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology